October 24, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in the radiation treatment of cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.

Powered by the world’s smallest self-shielded proton accelerator from Mevion, the MEVION S250-FIT will be the first and only full proton therapy system that can fit into an existing LINAC vault. The system will include industry-leading HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT), dual-energy wide-aperture diagnostic CT in the treatment position for IGRT and adaptive therapy, and FLASH research capabilities. It is also designed to support rapid access to emerging technologies such as ARC therapy.

Thanks to its compact size, the FIT system will further reduce the cost and complexity of proton therapy. As the name suggests, FIT will enable rapid deployment of an integrated design and bring the transformative power of proton therapy to more cancer centers.

“MEVION S250-FIT is a true quantum leap for proton accessibility. Placing high-quality proton therapy in a LINAC vault has always been a primary goal of bringing the cost of a proton closer to conventional X-ray, and as such, providing greater access to this important therapy,” said Jay Loeffler, MD, chairman emeritus of Mass General Hospital and co-chair of Mevion’s clinical and technical advisory board.

“I have seen the clinical benefits of proton therapy over the past 20 years, especially for pediatric patients, and the idea that proton therapy could be available to all pediatric patients has always been a dream of mine. I am so excited to hear about this innovation. This product could change the rules,” said Nancy Tarbell, MD, world-renowned pediatric radiation oncologist and CC Wang Professor Emeritus at Harvard Medical School and Mass.

The FIT system will be developed in partnership with Leo Cancer Care, a medical device company based in Middleton, Wisconsin, with offices in Europe and North America. Leo Cancer Care is focused on introducing a ‘more human’ approach to the delivery of radiotherapy and uses upright positioning to improve patient experience, clinical efficiency and access to radiotherapy.

“Mevion Medical Systems has a proven 18-year track record in technological innovation. We are excited to once again disrupt the industry by shrinking proton therapy even further and by making this coveted technology much more accessible to the patients who need it most. Imagine the potential to implement proton therapy at your cancer center within a year and fully integrate it with other radiation modalities,” said Tina Yu, MD, CEO and President of Mevion Medical Systems. “The Leo Cancer Care Upright Patient Positioning System complements Mevion’s core technologies very well. They share our vision to democratize proton therapy. We look forward to a long and fruitful partnership with Leo Cancer Care.”

“Leo Cancer Care, like Mevion, focuses on the patient experience. Together, Leo and Mevion agreed that we wanted to take proton therapy where we never thought it could go, and together we would achieve what was once thought impossible. By working with Mevion, we will be able to reduce proton therapy in size and cost so that it can be within the reach of the patients who will benefit the most from it,” said proton therapy champion and veteran entrepreneur Rock Mackey, d -r, Chairman of the Board and Co-Founder of Leo Cancer Care.

Mevion will officially introduce the MEVION S250-FIT Proton Therapy System at the ASTRO 64th Annual Meeting in San Antonio, Texas. Attendees are invited to join Mevion’s booth 566 unveiling at 2:00 PM CDT on October 23 and learn more about the system at the show from October 23-25.

* MEVION S250-FIT Proton Therapy System, FLASH Therapy, Online Adaptive Therapy and ARC Therapy are not yet available for clinical use.

For more information: https://www.mevion.com/

Find more ASTRO22 content here


Previous articlePensacola International Airport Expansion Project
Next articlePreparing testing lab for expansion, increasing jobs at new South Bay complex